The approval of Eli Lilly’s orforglipron, sold as Foundayo, has changed the discussion around oral GLP-1s. Until recently, the GLP-1 receptor was widely seen as a poor target for conventional small-molecule chemistry. Injectable peptides proved that the biology worked, but an oral small molecule that could deliver meaningful efficacy remained a much harder proposition. Foundayo’s approval on 1 April 2026 shows that this barrier can be overcome.
The commercial forecasts explain the excitement, Fidelity has put 2026 sales at $1.5bn to $2.8bn, Citi has forecast peak annual revenues above $40bn, and Clarivate projects $11.1bn in obesity sales across the G7 by 2031. After years in which the category has been shaped by peptide manufacturing constraints, injector supply and access problems, a tablet is an attractive prospect.
However, no sooner had the breakthrough is achieved, when thoughts moved to what the broader small-molecule GLP-1 agonist landscape will look like as it matures. Foundayo is unlikely to sit alone for long. If other programmes make it through the clinic, oral GLP-1s could become a genuine class rather than just a single blockbuster product. While this would change the commercial equation, it would also change the scientific and patent questions companies need to think about now.
Read the article in full here.
